DBV Technologies (DBVT) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
DBV Technologies stock (DBVT) is currently trading at $19.55. DBV Technologies PS ratio (Price-to-Sales) is 194.73. Analyst consensus price target for DBVT is $39.18. WallStSmart rates DBVT as Sell.
- DBVT PE ratio analysis and historical PE chart
- DBVT PS ratio (Price-to-Sales) history and trend
- DBVT intrinsic value — DCF, Graham Number, EPV models
- DBVT stock price prediction 2025 2026 2027 2028 2029 2030
- DBVT fair value vs current price
- DBVT insider transactions and insider buying
- Is DBVT undervalued or overvalued?
- DBV Technologies financial analysis — revenue, earnings, cash flow
- DBVT Piotroski F-Score and Altman Z-Score
- DBVT analyst price target and Smart Rating
DBV Technologies
📊 No data available
Try selecting a different time range
Smart Analysis
DBV Technologies (DBVT) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
DBV Technologies (DBVT) Key Strengths (1)
Revenue surging 158.80% year-over-year
Supporting Valuation Data
DBV Technologies (DBVT) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Very expensive at 194.7x annual revenue
Very expensive at 20.1x book value
Small-cap company with higher risk but more growth potential
Moderate institutional interest at 31.74%
Supporting Valuation Data
DBV Technologies (DBVT) Detailed Analysis Report
Overall Assessment
This company scores 23/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 1 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 2.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth. Growth metrics are encouraging with Revenue Growth at 158.80%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (194.73), Price/Book (20.10) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -234.10%, Operating Margin at -1236.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -234.10% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 158.80% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
DBVT Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
DBVT's Price-to-Sales ratio of 194.73x trades at a deep discount to its historical average of 1433.6x (65th percentile). The current valuation is 98% below its historical high of 9336.81x set in Jul 2015, and 9835% above its historical low of 1.96x in May 2024. Over the past 12 months, the PS ratio has expanded from ~132.7x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for DBV Technologies (DBVT) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
DBV Technologies is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 6M with 159% growth year-over-year.
Key Findings
Revenue growing at 159% YoY, reaching 6M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 487% of revenue (27M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -33M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can DBV Technologies maintain 159%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact DBV Technologies.
Bottom Line
DBV Technologies is a high-conviction growth story with revenue accelerating at 159% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About DBV Technologies(DBVT)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
DBV Technologies SA, a clinical-stage biopharmaceutical company, is dedicated to the research and development of epicutaneous immunotherapy products. The company is headquartered in Montrouge, France.